Impact Biomedical (IBO) Cash from Operations (2022 - 2026)

Impact Biomedical (IBO) has reported Cash from Operations for 5 consecutive years, with $470000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations rose 167.72% year-over-year to $470000.0; the trailing twelve-month figure through Jun 2026 stood at -$508000.0 (up 84.89% YoY), and the FY2025 full-year result was -$1.9 million, up 33.78% from the prior year.
• Cash from Operations climbed to $470000.0 in Q2 2026 per IBO's latest filing, from -$464000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at $470000.0 in Q2 2026 and bottomed at -$1.0 million in Q1 2023.
• Historically, Cash from Operations has averaged -$547125.0 across 5 years, with a median of -$642000.0 in 2023.
• The sharpest annual moves came in 2024 and 2026: Cash from Operations sank 127.71% in 2024, then soared 167.72% in 2026.
• Over 5 years, Cash from Operations stood at -$363000.0 in 2022, then retreated by 19.28% to -$433000.0 in 2023, then tumbled by 127.71% to -$986000.0 in 2024, then surged by 110.04% to $99000.0 in 2025, then soared by 374.75% to $470000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered $470000.0, -$464000.0, and $99000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.